SCHEMBL6437356

SCHEMBL6437356

COC(=O)C(C)(C)S(=O)(=O)N1CCC(c2ccc(-c3nccs3)c(C)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.50
MMP3 P08254 7/20 0.50
MMP1 P03956 2/20 0.49
MMP9 P14780 2/20 0.49
MMP14 P50281 2/20 0.49
FAAH O00519 1/20 0.37
EPHX2 P34913 1/20 0.37
MEN1 O00255 3/20 0.35
LMNA P02545 3/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPK1 P28482 2/20 0.35
USP2 O75604 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TSHR P16473 1/20 0.35
GAA P10253 1/20 0.34
CHRNA7 P36544 1/20 0.34
HTR3A P46098 1/20 0.34
KDM6B O15054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434601 0.90 MMP2 (0.48) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6971890 0.89 MMP2 (0.61) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6437057 0.89 MMP2 (0.47) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6437658 0.78 MMP2 (0.51) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6438199 0.78 MMP3 (0.62) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6590101 0.77 MMP2 (0.65) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6586527 0.77 MMP2 (0.71) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6972911 0.76 MMP2 (0.42) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6587846 0.76 MMP2 (0.83) MMP2MMP3MMP1MMP9MMP14
SCHEMBL6436990 0.76 MMP3 (0.69) MMP2MMP3MMP1MMP9MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1181017-B1 METALLOPROTEASE INHIBITORS PFIZER LTD (GB) 2003-04-16 EP disclosed
US-6511993-B1 Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes PFIZER INC. 2003-01-28 US disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 MMP2 19/4885MMP3 28/4885MMP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.